TP53 and neoplasm: Based on the localisation of this predicted gene, denoted APITD1 (APoptosis-Inducing, TAF9-like Domain 1), and the fact that TP53 mutations are rare in neuroblastoma tumours (Imamura et al, 1993; Komuro et al, 1993; Vogan et al, 1993; Hosoi et al, 1994), we hypothesised that loss of function for APITD1 could be a way for tumour cells to overcome the cell growth-regulating properties of the p53 pathway.